当前位置： SCI文献检索 > JOURNAL OF MEDICAL ECONOMICS期刊下所有文献 > Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients.

Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients.

Abstract：

AIM:This analysis assessed the direct medical costs of newly-diagnosed, temozolomide (TMZ)-treated glioblastoma (GBM) from the perspective of a US commercial setting. MATERIALS AND METHODS:The analysis included subjects identified from the IMS PharMetrics LifeLink Plus™ claims database from January 1, 2008 to August 31, 2014 who were ≥18 years of age, had ≥1 malignant brain cancer diagnosis, had brain surgery ≤90 days prior to TMZ initiation, had TMZ treatment, and were continuously enrolled for ≥12 months pre-diagnosis and ≥1 month post-diagnosis. Per-patient per-month (PPPM) and cumulative costs from 3 months pre-diagnosis to various post-diagnosis follow-up time points were calculated. Multivariable analyses were used to estimate adjusted mean cost and identify contributors of cost. RESULTS:The study included 2,921 subjects (median age = 56 years; 60% male). After diagnosis, the median (interquartile range, IQR) number of inpatient, emergency department, and outpatient visits were 2 (1-4), 1 (1-3), and 19 (13-27); median (IQR) length of stay per hospitalization was 5 (3-9) days. Mean total cumulative costs per patient from 3 months pre-diagnosis to 12 months and to 5 years post-diagnosis were $201,749 (197,490-206,024) and $268,031 (262,877-274,416). Mean (SD) PPPM costs were $818 (1,128) and $7,394 (8,676) pre- and post-GBM diagnosis, respectively. The variables most predictive of cumulative costs included radiation therapy (+$81,732), ≥2 weeks of hospitalization (+$49,629), and ≥7 MRI scans (+$40,105). CONCLUSIONS:The direct medical costs of newly-diagnosed, TMZ-treated GBM in commercially insured patients are substantial, with estimated total cumulative costs of $268,031.

journal_name

J Med Econ

journal_title

Journal of medical economics

authors

Jiang S,Hill K,Patel D,Waldeck AR,Botteman M,Aly A,Norden AD

doi

10.1080/13696998.2017.1364258

subject

Has Abstract

pub_date

2017-12-01 00:00:00

pages

1237-1243

issue

12

eissn

1369-6998

issn

1941-837X

journal_volume

20

pub_type

杂志文章

相关文献

JOURNAL OF MEDICAL ECONOMICS文献大全
  • Does an economic incentive affect provider behavior? Evidence from a field experiment on different payment mechanisms.

    abstract：AIMS:This study analyzed discrepancies in the quantity of medical services supplied by physicians under different payment systems for patients with different health statuses and illnesses by means of a field experiment. METHODS:Based on the laboratory experiment of Heike Hennig-Schmidt, we designed a field experiment ...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.1080/13696998.2018.1539399

    authors： Xi X,Wang E,Lu Q,Chen P,Wo T,Tang K

    更新日期：2019-01-01 00:00:00

  • Healthcare costs of fast-acting insulin analogues versus short-acting human insulin for Danish patients with type 2 diabetes on a basal-bolus regimen.

    abstract：AIMS:Fast-acting insulin analogues (FAIAs) reduce hypoglycaemia and improve administration flexibility compared with short-acting human insulin (SHI). This analysis examines whether these benefits translate into cost offsets when comparing the total treatment costs for FAIA versus SHI used as basal-bolus therapy for tr...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.3111/13696998.2011.588892

    authors： Christensen TE,Gundgaard J,Pilgaard T

    更新日期：2011-01-01 00:00:00

  • Comparison of treatment costs in inadequately controlled type 2 diabetes in Germany based on the APOLLO trial with insulin glargine.

    abstract：OBJECTIVE:A cost analysis of once-daily insulin glargine versus three-times daily insulin lispro in combination with oral antidiabetic drugs (OADs) for insulin-naive type 2 diabetes patients in Germany based on the APOLLO trial (A Parallel design comparing an Oral antidiabetic drug combination therapy with either Lantu...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.3111/13696990902949614

    authors： Bretzel RG,Dippel FW,Linn T,Neilson AR

    更新日期：2009-06-01 00:00:00

  • Cost of macrovascular complications in people with diabetes from a public healthcare perspective: a retrospective database study in Brazil.

    abstract：:Aims: To evaluate costs in patients with diabetes who experienced a macrovascular complication from a Brazilian public healthcare system perspective.Materials and methods: A retrospective, observational study that utilized the database of the Brazilian Unified Health System (DATASUS). Data for direct medical costs (ho...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.1080/13696998.2020.1764966

    authors： Julian GS,Campos D,Broe Honore J,Sauer Tobaruella F,Hyun Yoon J,Hallén N

    更新日期：2020-09-01 00:00:00

  • Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.

    abstract：:Aims: To evaluate total costs and health consequences of a colorectal cancer (CRC) screening program with colonoscopy, fecal immunochemical tests (FIT), and expanded use of multitarget stool DNA (mt-sDNA) from the perspectives of Integrated Delivery Networks (IDNs) and payers in the United States.Materials and methods...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.1080/13696998.2020.1730123

    authors： Hathway JM,Miller-Wilson LA,Jensen IS,Ozbay B,Regan C,Jena AB,Weinstein MC,Parks PD

    更新日期：2020-06-01 00:00:00

  • Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.

    abstract：OBJECTIVE:To estimate the cost-effectiveness of ipilimumab (3 mg/kg) compared with best supportive care (BSC) in pre-treated advanced melanoma patients. METHODS:The analysis was based on a US payer perspective and lifetime time horizon. A three-state Markov model was developed representing clinical outcomes, quality-o...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.3111/13696998.2012.739226

    authors： Barzey V,Atkins MB,Garrison LP,Asukai Y,Kotapati S,Penrod JR

    更新日期：2013-01-01 00:00:00

  • Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.

    abstract：OBJECTIVE:Basal insulin analogs are well established in the treatment of type 1 diabetes in Germany. However, little is known about their economic impact. The aim of this study for an adult population was to compare, from the perspective of the Statutory Health Insurance (SHI), the cost effectiveness of the long-acting...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.3111/13696998.2012.713879

    authors： Pfohl M,Schädlich PK,Dippel FW,Koltermann KC

    更新日期：2012-01-01 00:00:00

  • Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis.

    abstract：OBJECTIVE:To investigate adherence to dornase alfa therapy among commercially-insured patients with cystic fibrosis (CF) and to examine the impact of adherence on health and economic outcomes. METHODS:This retrospective cohort analysis included CF patients with ≥1 dornase alfa (Pulmozyme) pharmacy claim between 1 Octo...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.3111/13696998.2013.787427

    authors： Nasr SZ,Chou W,Villa KF,Chang E,Broder MS

    更新日期：2013-01-01 00:00:00

  • The effects of global budget on cost control and readmission in rural China: a difference-in-difference analysis.

    abstract：BACKGROUND:Global budget (GB) is considered one of the most important payment methods available. Since a new round of healthcare system reforms in 2009, the Chinese government has been paying attention to this prospective payment. However, it is unclear whether GB has influenced cost control and how it works in rural C...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.1080/13696998.2017.1336448

    authors： He R,Miao Y,Ye T,Zhang Y,Tang W,Li Z,Zhang L

    更新日期：2017-09-01 00:00:00

  • Costs of managing severe hypoglycaemia in three European countries.

    abstract：OBJECTIVES:To assess the costs of severe hypoglycaemic events (SHEs) in diabetes patients in Germany, Spain and the UK. METHODS:Healthcare resource use was measured by surveying 639 patients aged ≥ 16 years, receiving insulin for type 1 (n=319) or type 2 diabetes (n=320), who experienced ≥ 1 SHE in the preceding year....

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.3111/13696990903336597

    authors： Hammer M,Lammert M,Mejías SM,Kern W,Frier BM

    更新日期：2009-01-01 00:00:00

  • Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population.

    abstract：OBJECTIVE:To evaluate total annual all-cause, gastrointestinal-related, and symptom-related healthcare costs among chronic constipation (CC) patients and estimate incremental all-cause healthcare costs of CC patients relative to matched controls. METHODS:Patients aged ≥18 years with continuous medical and pharmacy ben...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.3111/13696998.2013.860375

    authors： Cai Q,Buono JL,Spalding WM,Sarocco P,Tan H,Stephenson JJ,Carson RT,Doshi JA

    更新日期：2014-02-01 00:00:00

  • Budget impact analysis of long acting injection for schizophrenia in Japan.

    abstract：:Aims: To estimate the budgetary impact of providing additional reimbursement for long acting injections for schizophrenia patients in psychiatric hospital settings in Japan to improve patient outcomes in schizophrenia.Methods: Budget impact analysis of change in reimbursement policy using a prevalence-based model over...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.1080/13696998.2020.1754229

    authors： Kasahara-Kiritani M,Chaturvedi A,Inagaki A,Wakamatsu A,Jung W

    更新日期：2020-08-01 00:00:00

  • Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States.

    abstract：OBJECTIVE:This study evaluated the overall burden of illness of chemotherapy-induced nausea and vomiting (CINV) and associated all-cause costs from a hospital's perspective (costs to the hospital) in patients with cancer treated with chemotherapy (CT) in the US hospital outpatient setting. METHODS:Patients with a canc...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.3111/13696998.2010.547237

    authors： Craver C,Gayle J,Balu S,Buchner D

    更新日期：2011-01-01 00:00:00

  • Outcomes associated with concordance of oral antidiabetic drug treatments to prescribing information in patients with type 2 diabetes mellitus and chronic kidney disease.

    abstract：OBJECTIVES:This retrospective study aims to examine the association between prescribing information (PI)-concordant oral antidiabetic drug (OAD) treatment and clinical and economic outcomes in patients with type 2 diabetes mellitus and stages 3-5 chronic kidney disease (CKD). METHODS:The study used a large, national a...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.3111/13696998.2013.775135

    authors： Chen SY,Lee YC,Alas V,Greene M,Brixner D

    更新日期：2013-01-01 00:00:00

  • Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet.

    abstract：BACKGROUND:Growing financial pressure on US dialysis providers requires economic efficiency considerations. The objective of this study was to examine short-term economic efficiencies of a cinacalcet-based treatment approach for secondary hyperparathyroidism. METHODS:This study retrospectively assessed cost per bioche...

    journal_title：Journal of medical economics

    pub_type： 杂志文章,随机对照试验

    doi：10.3111/13696998.2013.826665

    authors： Belozeroff V,Lee A,Tseng S,Chiroli S,Campbell JD

    更新日期：2013-09-01 00:00:00

  • A systematic review of pharmacoeconomic guidelines.

    abstract：OBJECTIVE:To review, summarize, and analyze both similarities and differences of pharmacoeconomic (PE) guidelines, to enable researchers to access their characteristics and the current state of PE guidelines; furthermore, to learn which methodological issues still remain contested and to promote the methodological deve...

    journal_title：Journal of medical economics

    pub_type： 杂志文章,评审

    doi：10.1080/13696998.2017.1387118

    authors： Zhao Y,Feng HM,Qu J,Luo X,Ma WJ,Tian JH

    更新日期：2018-01-01 00:00:00

  • Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis.

    abstract：BACKGROUND:Biologic treatments have enhanced the treatment outcomes of patients with active ankylosing spondylitis (AS). Until recently, TNF-alpha-inhibitors have been the only biologics approved for the treatment of active AS. The objective of this study was to assess the potential financial impact of the first non-TN...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.1080/13696998.2018.1551227

    authors： Purmonen T,Törmälehto S,Wahlman H,Puolakka K

    更新日期：2019-02-01 00:00:00

  • The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment.

    abstract：OBJECTIVE:To critically evaluate published cost-effectiveness studies of novel drug products requiring less-frequent medication dosing compared to conventional formulations of the same drug substance. METHODS:A search was conducted in the Medline and Embase databases for cost-effectiveness studies published before May...

    journal_title：Journal of medical economics

    pub_type： 杂志文章,评审

    doi：10.3111/13696991003757500

    authors： Cheng MM,Alfonso R,Best JH,Garrison LP,Bruhn D,Veenstra DL

    更新日期：2010-01-01 00:00:00

  • Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain.

    abstract：OBJECTIVE:The treatment of iron deficiency (ID) with ferric carboxymaltose (FCM) improves the functional class and quality of life of chronic heart failure (CHF) patients with reduced left ventricular ejection fraction (LVEF), and reduces the rate of hospitalization due to worsening CHF. This study aims to evaluate the...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.1080/13696998.2020.1838872

    authors： Delgado JF,Oliva J,González-Franco Á,Cepeda JM,García-García JÁ,González-Domínguez A,Garcia-Casanovas A,Jiménez Merino S,Comín-Colet J

    更新日期：2020-10-30 00:00:00

  • Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.

    abstract：OBJECTIVE:To carry out a cost-utility analysis comparing initial treatment with solifenacin 5 mg/day vs oxybutynin immediate-release (IR) 15 mg/day for the treatment of patients with overactive bladder (OAB) from the perspective of the U.K. National Health Service (NHS). METHODS:A Markov model with six health states w...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.3111/13696998.2013.829079

    authors： Hart WM,Abrams P,Munro V,Retsa P,Nazir J

    更新日期：2013-10-01 00:00:00

  • Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.

    abstract：OBJECTIVE:Few studies have examined the costs associated with differing first-line chemotherapy regimens in patients with metastatic breast cancer (MBC). This study compares the relative cost impact of women starting first-line chemotherapy with capecitabine versus taxanes. METHODS:Women receiving first-line chemother...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.3111/13696990903269673

    authors： Camacho FT,Wu J,Wei W,Kimmick G,Anderson RT,Balkrishnan R

    更新日期：2009-09-01 00:00:00

  • Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.

    abstract：OBJECTIVE:The ECHELON-1 trial demonstrated efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as frontline therapy for stage III/IV classical Hodgkin lymphoma. This analysis evaluated the cost-effectiveness o...

    journal_title：Journal of medical economics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1080/13696998.2018.1542599

    authors： Delea TE,Sharma A,Grossman A,Eichten C,Fenton K,Josephson N,Richhariya A,Moskowitz AJ

    更新日期：2019-02-01 00:00:00

  • Cost of operating room time for endovascular transcatheter aortic valve replacement.

    abstract：:Background: Procedural efficiencies can contribute to cost reductions in transcatheter aortic valve replacement procedures (TAVR). The objective of this study is to determine operating room (OR) variable cost per minute in endovascular TAVR procedures, in a real-world hospital setting. Methods: Using Premier data from...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.1080/13696998.2019.1627364

    authors： Potter BJ,Ann Thompson C

    更新日期：2019-10-01 00:00:00

  • Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective.

    abstract：AIM:To evaluate the cost-effectiveness of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, compared to other clinically used biologics (adalimumab, infliximab, and ustekinumab) in Japan for the treatment of moderate-to-severe psoriasis from the healthcare system (total costs) and patient co-payment ...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.1080/13696998.2018.1532905

    authors： Igarashi A,Igarashi A,Graham CN,Gilloteau I,Tani Y

    更新日期：2018-10-26 00:00:00

  • Effectiveness of mobile application for menstrual management of working women in Japan: randomized controlled trial and medical economic evaluation.

    abstract：AIMS:Hormonal imbalances can affect a woman's physical and mental condition, impacting her daily life and productivity. A mobile application, "Karada-no-kimochi", predicts the menstrual cycle based on recorded data, and provides the information regarding menstruation. This study investigates the effectiveness of the ap...

    journal_title：Journal of medical economics

    pub_type： 杂志文章,随机对照试验

    doi：10.1080/13696998.2018.1515082

    authors： Song M,Kanaoka H

    更新日期：2018-11-01 00:00:00

  • Costs of hospital events in patients with metastatic colorectal cancer.

    abstract：BACKGROUND:In the last decade, the number of new agents, including monoclonal antibodies, being developed to treat metastatic colorectal cancer (mCRC) increased rapidly. While improving outcomes, these new treatments also have distinct and known safety profiles with toxicities that may require hospitalizations. However...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.3111/13696998.2011.610394

    authors： Overbeek JA,Zhao Z,van Herk-Sukel MP,Barber BL,Gao S,Herings RM

    更新日期：2011-01-01 00:00:00

  • Long-term health-related burden of adult congenital heart diseases in Hong Kong.

    abstract：:Aims: This study aimed to examine the long-term clinical and economic burden of adults with congenital heart disease (ACHD) in Hong Kong. Methods: It retrospectively analyzed 336 consecutive ACHD patients who attended the Adult Congenital Heart Clinic between January 1, 2009 and December 31, 2014. Direct medical costs...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.1080/13696998.2019.1613239

    authors： Lee VWY,Yan BP,Fong TMC,Fung AKP,Cheng FWT

    更新日期：2019-08-01 00:00:00

  • Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release.

    abstract：PURPOSE:To model the economic impact of annual relapses/relapse-related hospitalizations among adults with schizophrenia treated with lurasidone or quetiapine extended-release (XR). METHODS:A probabilistic model estimating per-patient-per-year (PPPY) direct mental healthcare (MH) cost differences due to relapses/relap...

    journal_title：Journal of medical economics

    pub_type： 杂志文章,随机对照试验

    doi：10.3111/13696998.2013.809353

    authors： Rajagopalan K,O'Day K,Meyer K,Pikalov A,Loebel A

    更新日期：2013-08-01 00:00:00

  • Assessing the burden of nocturia in the workplace: the associations between nocturnal voiding, subjective well-being, work engagement and productivity.

    abstract：:Aims: Nocturia (getting up at night to urinate, where each urination being followed by sleep or intention to sleep) is a bothersome symptom with potentially negative consequences for individual health and daytime functioning. This study assessed the burden of nocturia in the workplace by investigating associations bet...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.1080/13696998.2020.1767631

    authors： Hafner M,Andersson FL,Burtea T,van Stolk C,Whitmore M,Yerushalmi E,Troxel WM

    更新日期：2020-09-01 00:00:00

  • Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon β-1a.

    abstract：AIM:Disease-modifying therapies (DMTs) impact the natural history of relapsing forms of multiple sclerosis (RRMS) by reducing annual relapse rates and slowing disability progression. The effect of DMTs on indirect costs has not been consistently explored in cost-effectiveness studies thus far. The value to patients of ...

    journal_title：Journal of medical economics

    pub_type： 杂志文章

    doi：10.1080/13696998.2017.1357564

    authors： Frasco MA,Shih T,Incerti D,Diaz Espinosa O,Vania DK,Thomas N

    更新日期：2017-10-01 00:00:00